PL2442647T3 - Związki ditiolowe, pochodne i ich zastosowania - Google Patents

Związki ditiolowe, pochodne i ich zastosowania

Info

Publication number
PL2442647T3
PL2442647T3 PL10790038.3T PL10790038T PL2442647T3 PL 2442647 T3 PL2442647 T3 PL 2442647T3 PL 10790038 T PL10790038 T PL 10790038T PL 2442647 T3 PL2442647 T3 PL 2442647T3
Authority
PL
Poland
Prior art keywords
derivatives
uses therefor
dithiol compounds
dithiol
compounds
Prior art date
Application number
PL10790038.3T
Other languages
English (en)
Inventor
William Garner
Margaret Garner
George Minno
David Gooden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2442647T3 publication Critical patent/PL2442647T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10790038.3T 2009-06-15 2010-06-15 Związki ditiolowe, pochodne i ich zastosowania PL2442647T3 (pl)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US18700509P 2009-06-15 2009-06-15
US18694009P 2009-06-15 2009-06-15
US18703309P 2009-06-15 2009-06-15
US18702809P 2009-06-15 2009-06-15
US18703909P 2009-06-15 2009-06-15
US18702309P 2009-06-15 2009-06-15
US18698609P 2009-06-15 2009-06-15
US18701809P 2009-06-15 2009-06-15
US22493009P 2009-07-13 2009-07-13
US23505109P 2009-08-19 2009-08-19
US23791209P 2009-08-28 2009-08-28
US24223209P 2009-09-14 2009-09-14

Publications (1)

Publication Number Publication Date
PL2442647T3 true PL2442647T3 (pl) 2016-09-30

Family

ID=43357007

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10790038.3T PL2442647T3 (pl) 2009-06-15 2010-06-15 Związki ditiolowe, pochodne i ich zastosowania

Country Status (5)

Country Link
US (4) US8795706B2 (pl)
EP (4) EP4082542A1 (pl)
DK (1) DK2442647T3 (pl)
PL (1) PL2442647T3 (pl)
WO (1) WO2010147957A2 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
EP2442645B1 (en) 2009-06-15 2014-08-27 Encore Health, Llc Choline esters
EP4082542A1 (en) 2009-06-15 2022-11-02 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
NZ610378A (en) * 2010-11-18 2015-05-29 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
TWI588560B (zh) 2012-04-05 2017-06-21 布萊恩荷登視覺協會 用於屈光不正之鏡片、裝置、方法及系統
US9201250B2 (en) 2012-10-17 2015-12-01 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
JP2015533430A (ja) 2012-10-17 2015-11-24 ブリエン ホールデン ビジョン インスティテュートＢｒｉｅｎ Ｈｏｌｄｅｎ Ｖｉｓｉｏｎ Ｉｎｓｔｉｔｕｔｅ 屈折異常用のレンズ、デバイス、方法、及びシステム
CA2891261C (en) 2012-11-15 2023-04-04 Brandeis University Tethering cysteine residues using cyclic disulfides
MX384877B (es) 2014-03-03 2025-03-14 Novartis Ag Composiciones de éster de colina de ácido lipoico y métodos de uso.
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016164534A1 (en) * 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2016176089A1 (en) * 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
CA2985014C (fr) * 2015-05-21 2024-01-16 Ophtalmis Monaco Composition ophtalmique comprenant de l'acide lipoique et un polymere muco-mimetique
US10711261B2 (en) 2015-08-18 2020-07-14 Brandeis University Tethering cysteine residues using cyclic disulfides
EP3509599A4 (en) 2016-09-08 2020-02-19 Sabila Biosciences LLC 1,2-DITHIOLANE COMPOUNDS USEFUL IN NEUROPROTECTION, DISEASES AND AUTOIMMUNE AND CANCER CONDITIONS
JOP20190057A1 (ar) * 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
CA3061203A1 (en) 2017-04-25 2018-11-01 Ischemix Llc Compositions and methods for treating traumatic brain injury
CN107089967A (zh) * 2017-05-12 2017-08-25 苏州富士莱医药股份有限公司 一种r‑硫辛酸胆碱酯卤化物的制备方法
CN108822077A (zh) * 2018-08-07 2018-11-16 苏州富士莱医药股份有限公司 一种r-硫辛酸胆碱酯卤化物的精制方法
CN108586429A (zh) * 2018-08-07 2018-09-28 苏州富士莱医药股份有限公司 R-硫辛酸胆碱酯卤化物的纯化精制方法
CA3123370A1 (en) * 2018-12-18 2020-06-25 Santen Pharmaceutical Co., Ltd. Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
CA3123378A1 (en) * 2018-12-18 2020-06-25 Santen Pharmaceutical Co., Ltd. Agent containing 4-phenylbutyrate, for preventing or treating presbyopia
TW202103696A (zh) 2019-04-17 2021-02-01 日商參天製藥股份有限公司 硫辛酸前藥
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
KR20230015955A (ko) 2020-05-26 2023-01-31 산텐 세이야꾸 가부시키가이샤 노시의 치료 또는 예방에 유용한 황 함유 화합물
MX2023002946A (es) * 2020-09-11 2023-04-11 Intratus Nevada Inc Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida.
CN115536631B (zh) * 2021-06-30 2024-01-30 江苏同禾药业有限公司 一种高纯度的右旋硫辛酸镁盐的制备方法
WO2024059754A1 (en) * 2022-09-14 2024-03-21 Quantapore, Inc. Polythiolated linkers for stable nanoparticle suspensions and uses thereof
KR102701383B1 (ko) * 2022-11-11 2024-09-04 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
EP4616853A1 (en) * 2022-11-11 2025-09-17 Medicibio Co., Ltd Lipo-hydroxamic acid derivative and pharmaceutical use thereof
EP4683625A2 (en) * 2023-03-20 2026-01-28 The Trustees Of Columbia University In The City Of New York Prevention and treatment of conditions using ethyl pyruvate
GB202305212D0 (en) * 2023-04-06 2023-05-24 Elixa Mediscience Ltd Compounds
US12152174B2 (en) 2023-04-13 2024-11-26 The Regents Of The University Of California Adjustably stable adhesive compositions for medical and non-medical uses, and recycling
CN117263907B (zh) * 2023-09-23 2026-01-27 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用
WO2025264886A1 (en) * 2024-06-19 2025-12-26 Btv Holding, Llc Ophthalmic preparations and methods of use
US12269925B1 (en) 2024-08-13 2025-04-08 The Regents Of The University Of California Fast curing, biocompatible and biodegradable adhesives and sealants

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1043604A (en) 1911-04-05 1912-11-05 Julius Orwan Clothes-line hanger.
GB935962A (en) * 1960-06-17 1963-09-04 Fujisawa Pharmaceutical Co Improvements in or relating to the production of 6.8-dithiooctanamides
US3387008A (en) 1965-06-28 1968-06-04 Eastman Kodak Co Process for making a substantially ester free fatty acid alkanolamide product
US3855240A (en) * 1969-04-28 1974-12-17 Exxon Research Engineering Co Sulfur containing heterocycles
US4210667A (en) * 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
US4755528A (en) * 1984-12-06 1988-07-05 Alcon Laboratories, Inc. High energy ionizing protective 2,3-diamino-1,4-butanedithiol; 4,5-diamino-1,2-dithiane; and N-acyl and N-alkyl derivatives thereof, compositions and method of use therefor
US6030950A (en) * 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
FR2638970A1 (fr) 1988-11-16 1990-05-18 Corbiere Jerome Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention
JPH0732323B2 (ja) 1989-05-30 1995-04-10 住友金属鉱山株式会社 共振周波数の温度係数を調整可能な共振器
WO1993002639A1 (en) * 1991-08-06 1993-02-18 Autogenesis Technologies, Inc. Injectable collagen-based compositions for making intraocular lens
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU4633793A (en) 1992-06-10 1994-01-04 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
AU4653993A (en) * 1992-07-02 1994-01-31 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
WO1994001773A1 (en) 1992-07-06 1994-01-20 Biomira Inc. Photoactivation of proteins for conjugation purposes
US5354331A (en) * 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
US5465737A (en) * 1992-07-15 1995-11-14 Schachar; Ronald A. Treatment of presbyopia and other eye disorders
WO1994003129A1 (en) * 1992-08-07 1994-02-17 Keravision Inc. Hybrid intrastromal corneal ring
DE4345199C2 (de) * 1993-05-22 1995-10-12 Asta Medica Ag Verwendung von Dihydroliponsäure zur Unterdrückung von Unverträglichkeitsreaktionen im Grenzbereich von Implantaten mit lebendem Körpergewebe
US5395356A (en) * 1993-06-04 1995-03-07 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
US5527774A (en) * 1993-07-12 1996-06-18 Girard; Louis J. Dislocation of cataractous lens by enzymatic zonulolysis
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
AU704591B2 (en) * 1994-04-04 1999-04-29 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
ATE185842T1 (de) 1994-07-18 1999-11-15 Dsm Nv Verfahren zur herstellung von beta-lactamen mit dauernd hochkonzentrierten reagenzien
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5624955A (en) * 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5686450A (en) * 1995-06-07 1997-11-11 Alcon Laboratories, Inc. Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
IL128079A0 (en) * 1996-07-22 1999-11-30 Monsanto Co Thiol sulfone metalloprotease inhibitors
US6007510A (en) * 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
US5817630A (en) * 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
AU728488B2 (en) * 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
US5843184A (en) * 1998-01-26 1998-12-01 Cionni; Robert J. Endocapsular tension ring and method of implanting same
US6153647A (en) 1998-11-12 2000-11-28 My-Tech, Inc. Method for augmenting the inotropic effects of β-adrenergic agonists using pyruvate therapy
US6472541B2 (en) * 1998-11-20 2002-10-29 The Regents Of The University Of California Protecting groups with increased photosensitivities
AU758903B2 (en) * 1998-11-26 2003-04-03 Pentapharm Ag Transport system conjugate
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
AU5601300A (en) * 1999-06-09 2000-12-28 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
US6906210B2 (en) * 2000-08-02 2005-06-14 Basf Aktiengesellschaft Method for producing lipoic acid and dihydrolipoic acid
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US6923955B2 (en) 2000-08-16 2005-08-02 Newlens, Llc Presbyopia treatment by lens alteration
WO2002013863A2 (en) 2000-08-16 2002-02-21 Refocus, Llc. Presbyopia treatment by lens alteration
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20050112113A1 (en) 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
DE10045059A1 (de) * 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
US6703039B2 (en) * 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
CA2435374A1 (en) 2001-01-19 2002-07-25 Newlens, Llc Presbyopia treatment by reducing and preventing lenticular disulfide crosslinks
US7700080B2 (en) * 2001-03-19 2010-04-20 Senju Pharmaceutical Co., Ltd. Method of suppressing melanin production by metal chelates of lipoyl amino acid derivatives
CA2448062A1 (en) * 2001-05-25 2002-12-05 Ceremedix, Inc. Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
WO2003084532A1 (en) 2002-04-03 2003-10-16 Avery Mitchell A Lipoic acid analogs useful as provitamins and antioxidants
US20050137124A1 (en) * 2002-08-09 2005-06-23 Vitreo-Retinal Technologies, Inc. A California Corporation Agents for intravitreal administration to treat or prevent disorders of the eye
KR100973450B1 (ko) * 2002-09-13 2010-08-02 유겐가이샤 오가 리서치 멜라닌 소거제
EP1551399A4 (en) 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
AU2004293477A1 (en) 2003-11-25 2005-06-09 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US7718697B2 (en) 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060188492A1 (en) * 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
AU2006270035A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents
US20070055070A1 (en) * 2005-09-07 2007-03-08 Lawrence Lowell J Novel esters of lipoic acid
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
US7973073B2 (en) * 2006-06-16 2011-07-05 Indigene Pharmaceuticals, Inc. Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
ES2732293T3 (es) * 2007-02-22 2019-11-21 Childrens Hospital & Res Center At Oakland Formulaciones de ácidos grasos y métodos para el uso de las mismas
WO2008106640A1 (en) * 2007-03-01 2008-09-04 Cedars-Sinai Medical Center Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof
UA86441C2 (ru) 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
EP2442645B1 (en) * 2009-06-15 2014-08-27 Encore Health, Llc Choline esters
EP4082542A1 (en) 2009-06-15 2022-11-02 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor

Also Published As

Publication number Publication date
WO2010147957A3 (en) 2011-03-03
WO2010147957A2 (en) 2010-12-23
EP3542629A2 (en) 2019-09-25
US8795706B2 (en) 2014-08-05
EP2442647B1 (en) 2016-03-16
EP2442647A4 (en) 2012-09-19
DK2442647T3 (en) 2016-05-30
US9567314B2 (en) 2017-02-14
US20100317608A1 (en) 2010-12-16
EP3542629A3 (en) 2020-01-01
EP4082542A1 (en) 2022-11-02
EP2442647A2 (en) 2012-04-25
US20150246903A9 (en) 2015-09-03
US20160264545A1 (en) 2016-09-15
EP3069612A2 (en) 2016-09-21
EP3069612A3 (en) 2016-10-19
US10039743B2 (en) 2018-08-07
US20140357691A1 (en) 2014-12-04
US20170231951A1 (en) 2017-08-17
US9284305B2 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
EP2442647A4 (en) DITHIOL COMPOUNDS, DERIVATIVES AND USES THEREOF
AP2012006216A0 (en) Benzimidazole-imidazole derivatives.
IL217956A0 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en) 5-fluoropyrimidinone derivatives
PT2308877E (pt) Derivados de imidazopiridin-2-ona
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL208336A0 (en) Pyrisazinone derivatives
ZA201106855B (en) Oxasiazole derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
ZA201101236B (en) New 2-amidothiadiazole derivatives
ZA201100948B (en) Acylaminobenzamide derivatives
IL217952A0 (en) N1-acyl-5-fluoropyrimidinone derivatives
IL213927A0 (en) Deoxyactagardine derivatives
SI2513119T1 (sl) 3,4,4a,10b-tetrahidro-1H-tiopirano-(4,3-c)izokinolinski derivati
IL216761A0 (en) Pyrazinooxazepine derivatives
IL208548A0 (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
IL219623A0 (en) [1,5]-diazocin derivatives
ZA201104279B (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives
GB0816145D0 (en) a-Galactosylceramide derivatives
GB0821711D0 (en) Dihydroindolone derivatives
HU0800376D0 (en) Sulfonyl-quinoline derivatives